Quantcast
Last updated on April 18, 2014 at 5:30 EDT

Latest CD135 Stories

2013-06-26 08:31:25

SAN DIEGO, June 26, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18(th) Congress of the European Hematology Association in Stockholm, Sweden. Data presented included analyses of patients with relapsed or refractory acute myeloid leukemia (AML) from a Phase 2 clinical trial of quizartinib as monotherapy. In the study,...

2013-06-25 04:21:15

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing...

2013-06-04 08:29:26

Phase 3 Clinical Trial in FLT3-ITD Positive Relapsed/Refractory AML Patients Planned for Early 2014 CHICAGO, June 4, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that multiple presentations from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were presented at the Annual Meeting of the American Society of Clinical Oncology. Data presented included analyses of the 333 patients with relapsed or refractory acute myeloid leukemia...

2013-05-22 08:28:18

SAN DIEGO, May 22, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective FLT3 inhibitor, will be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 31 through June 4, 2013, at McCormick Place in Chicago. Information about the abstracts, including presentation time and location, is listed below. Abstracts can be viewed online at...

2013-05-16 08:28:09

SAN DIEGO, May 16, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per share. Ambit has granted the underwriters a 30-day option to purchase up to an additional 1,218,750 shares at the initial public offering price to cover over-allotments, if any. Ambit's common stock is scheduled to begin trading on The NASDAQ Global Market on May 16, 2013, under the symbol "AMBI." The joint...

2013-03-12 00:20:48

TOKYO and SAN DIEGO, March 12, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013. Astellas has exercised its right to terminate the worldwide license agreement signed in 2009, and over the months ahead the companies will work together to...

2013-01-30 12:26:52

BURLINGTON, Mass., Jan. 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts the launch of new agents positioned for the treatment of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) through 2018. According to two Niche Markets and Rare Diseases reports, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, novel targeted therapies hold the most promise for...

2012-12-10 20:21:14

ATLANTA, Dec. 10, 2012 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH). The Phase 2 ACE study recruited...

2012-12-10 16:52:14

'It caught us by surprise, how well this works.' -- Mark Levis, M.D., Ph.D. A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins...

2012-11-06 08:28:10

TOKYO and SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation (Ambit) today announced that five oral presentations and three poster presentations highlighting the findings from multiple clinical and translational research studies with the investigational agent, quizartinib (AC220), will be presented at the American Society of Hematology (ASH) 54(th)Annual Meeting, December 8 - 11, 2012, at the Georgia World Congress Center in...